RBC, Stifel were the bookrunners; Canaccord Genuity, Needham assisted
By Devika Patel
Knoxville, Tenn., Oct. 30 - Aerie Pharmaceuticals, Inc. said the underwriters for its initial public offering of stock opted to exercise the deal's $10.08 million greenshoe in full for total proceeds of $77.28 million. The deal was announced Sept. 17 and priced for $67.2 million with the greenshoe on Oct. 25.
The company sold 7,728,000 common shares at $10.00 apiece. Of the shares, 1,008,000 were part of the fully exercised greenshoe.
RBC Capital Markets and Stifel were the joint bookrunning managers.
Proceeds will be used for clinical trials, working capital and general corporate purposes.
The clinical-stage pharmaceutical company is based in Bedminster, N.J. It intends to list its common stock on the Nasdaq under the symbol "AERI."
| Issuer: | Aerie Pharmaceuticals, Inc.
|
| Issue: | Common stock
|
| Amount: | $77.28 million (including $10.08 million greenshoe)
|
| Shares: | 7,728,000
|
| Price: | $10.00
|
| Warrants: | No
|
| Bookrunners: | RBC Capital Markets and Stifel
|
| Co-managers: | Canaccord Genuity Inc. and Needham & Co.
|
| Announcement date: | Sept. 17
|
| Pricing date: | Oct. 25
|
| Settlement date: | Oct. 30
|
| Stock exchange: | Nasdaq: AERI
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
